Media Search:



Texas Firearm Carry Act of 2021: Can Employers Bar Employees From Carrying Guns Onto Work Premises? – JD Supra

Texas Governor Greg Abbott is expected to sign the Firearm Carry Act of 2021 (House Bill 1927) into law. Texas will join several other states that have enacted or plan to enact similar permitless, constitutional carry statutes in support of the individual right to keep and bear arms under the Second Amendment of the U.S. Constitution. The act, which will go into effect on September 1, 2021, allows individuals 21 years of age and older to possess and carry a handgun in public without a government-issued permit or license, provided they are not otherwise prohibited from possessing a firearm under state or federal law. The new law still prohibits Texans from carrying a firearm in bars, amateur or professional sporting events, prisons, civil commitment facilities, state-run hospitals and nursing facilities, and amusement parks. However, it is now legal for Texans to carry a firearm at public governmental meetings.

Similar to existing open and concealed carry laws relating to licensed firearm carriers, the act also provides Texas business owners the right to prevent members of the public from bringing firearms into their places of business. The law makes it a Class C misdemeanor for individuals to carry a firearm into a business if they have oral or written notice that entry with a firearm is prohibited. The act provides specific language that business owners can use and post to effectuate this notice.

On the employment front, the act does not substantively amend Section 52.062(b) of the Texas Labor Code, which allows employers to prohibit an employee from possessing a firearm on their premises. An employers premises is defined as a building or a portion of a building, but does not include any public or private driveway, street, sidewalk or walkway, parking lot, parking garage, or other parking area. The new law also does not affect an employers immunity from civil liability for injuries or deaths arising out of an occurrence involving a firearm or ammunition that the employer is required to allow on [its] property, or the presumption that the presence of a firearm does not by itself constitute a failure by the employer to provide a safe workplace.

The Firearm Carry Act will come almost 10 years after the state allowed licensed Texas employees to store guns in their locked, private vehicles despite their employers ban of possession on their premises. Then-attorney general Abbott was a vocal proponent of employee gun rights, and has only broadened his support for Texans rights under the Second Amendment since taking the states highest office. Nevertheless, the new law that will be signed by Governor Abbott preserves the right of Texas employers to decide whether to allow firearms on their premises.

The Firearms Carry Act is likely to receive significant media attention that will raise many questions from employees. Like many new lawsespecially those involving hot-button issues such as guns in the workplaceemployers may want to get out in front of this act with a clear pronouncement of their positions and policies. In this case, the message can be simple: despite the hype, the new law does not change anything with regard to how we do business.

Read more from the original source:
Texas Firearm Carry Act of 2021: Can Employers Bar Employees From Carrying Guns Onto Work Premises? - JD Supra

SCOTUS asked to take up State v. Weber, Ohio case with Second Amendment implications – Buckeye Firearms Association

A man whose conviction for holding an unloaded shotgun in his home while drunk was upheld by the Ohio Supreme Court is taking his case to the Supreme Court of the United States (SCOTUS).

The case is State v. Weber, which as has been noted on our site, "involves a situation where despite the defendants wife telling police there was no longer a problem, they pressed their way in. There they found her admittedly inebriated but nonthreatening husband who, while he did have a shotgun, told police it was not loaded, which they proved for themselves."

Weber was charged with violating R.C. 2923.15(A), which states: No person, while under the influence of alcohol or drugs of abuse, shall carry or use any firearm or dangerous ordnance.

After a bench trial, Weber was found guilty and sentenced to 10 days in jail with all 10 days suspended. He also was placed on community control for one year, ordered to complete eight hours of community service, and fined $100.

When the Twelfth District Court of Appeals court upheld his conviction, it ruled as follows:

Furthermore, R.C.2923.15 does not, as suggested by appellant, criminalize the mere presence of a firearm in the home of an intoxicated person. Nor does the statute, as suggested by appellant, prohibit a person from carrying or using a firearm after consuming alcoholic beverages. Rather, the statute only prohibits the use or carrying of a firearm by a person who has imbibed to the point of intoxication.

Mr. Weber appealed to the Ohio Supreme Court, and that body narrowly ruled against him as well.

In a dissenting opinion, joined by Justices Sharon L. Kennedy and Judith L. French, Justice Patrick F. Fischer write that courts have been divided about the proper way to test the constitutionality of firearm laws since the U.S. Supreme Court issued its landmark District of Columbia v. Heller decision in 2008. He observed the Weber decision follows an interest-balancing test created by federal courts. He suggested Ohio adopt another approach that focuses on the text, history, and tradition of the Second Amendment to see if the challenged law or rule is consistent with the scope of the right as originally understood.

Justice Fischer also noted that state and federal courts would benefit from more clarity from SCOTUS on how to evaluate challenges to laws claiming to violate the Second Amendment. He wrote that instead of using the convoluted two-step approach, the Court should follow the Heller and McDonald decisions and look at the text, history, and tradition of the Second Amendment.

Justice Patrick DeWine concurred in the majority opinion, but also argued separately that the majority's analysis was not protective of Second Amendment rights because it "improperly applied an 'interest balancing' test rather than evaluate the challenged restriction based upon the original understanding of the Second Amendment," according to the court.

If Weber's petition for a writ of certiorari with the U.S. Supreme Court is granted, those calling for SCOTUS to provide clarity may get their wish. Weber is asking the court to determine the proper standard of constitutional review of a law that impacts the core value of the Second Amendment.

"The disagreement in the Ohio Supreme Court is emblematic of the confusion gripping the nation's lower courts," he wrote. "But confusion is not the only problem. The outcome of a wrongfully applied standard can significantly dilute the core protection of the Second Amendment."

As firearms rights advocate David Codrea wrote when covering this case for AmmoLand.com:

The point of intoxication, as defined by Ohios OVI laws is a Blood Alcohol Content of 0.08, or 0.02 if under 21. Significantly, a citizen old enough to serve in the military can reach that level after only one drink. And its fair to ask how many of us, especially with the holidays approaching, will be inclined to consume several adult beverages over the course of a family gathering. What if youre carrying, and not all blurry-eyed and speech-slurring like the hapless Mr. Weber was reported to be, but just right there at the legal limit for driving? Where is the compelling state interest to define that as the limit point?

...

"Still, this isnt a popular case for most 'gun rights' lobbying groups to make a big noise defendingwho wants to endure the optics of arguing guns for drunks? Regardless, the fact remains that there are already ways to deal with people who brandish, and who attack others with weapons. This isnt about public safety, its about another inroad to citizen disarmament. As for people who have proven they cant or wont control themselves, taking their tools but leaving them able to harm others is never the solution."

Chad D. Baus served as Buckeye Firearms Association Secretary from 2013-2019. He is co-founder of BFA-PAC, and served as its Vice Chairman for 15 years. He is the editor of BuckeyeFirearms.org, which received the Outdoor Writers of Ohio 2013 Supporting Member Award for Best Website, and is also an NRA-certified firearms instructor.

Related Articles:

Does Ohio Supreme Court ruling threaten right to bear arms in own home?

Gun and Alcohol Case Could Put Citizens at Risk in Their Own Homes

Go here to see the original:
SCOTUS asked to take up State v. Weber, Ohio case with Second Amendment implications - Buckeye Firearms Association

Project updates for the Week of June 7, 2021 – Texas Department of Transportation

TYLER TxDOT is planning to conduct the following construction and maintenance work in the district during the Week of June 7, 2021. Work schedules are subject to change due to weather conditions, equipment failure, or other unforeseen issues. Slow down and pay attention in work zones.

----------------------------------------

Seal coat operations continue around the Tyler District. Motorists should expect lane closures and delays during this work to seal and protect roadways from water, and to provide a longer life cycle. Various project work will be conducted with slow-moving mobile operations. Crews will be working in Cherokee, Henderson, Rusk, and Van Zandt counties throughout the week. Information on specific work locations is available in the Van Zandt County section of this release.

----------------------------------------

Anderson County Palestine Maintenance plans to conduct base repairs and level up on FM 3224. Expect lane closures with flaggers and a pilot car managing traffic control.

Anderson County construction projects updates:

County Road Off-System Bridge Project

Limits: Various locations in Anderson County

Contractor: Stateline Construction, LLC

Cost: $1.5 million

Anticipated Completion Date: Summer 2021

Final cleanup activities are ongoing on the CR 458 and CR 468 bridges and roadway elements. The project consists of construction of bridges, storm sewer, guardrail, base, pavement surfaces, and pavement markings.

US 79 Super 2 Project

Limits: From 0.5 mile northeast of Loop 256 to the Anderson/Cherokee County line

Contractor: Madden Contracting Company, LLC

Cost: $14.4 million

Anticipated Completion Date: Spring 2022

Work is ongoing on the shoulders and driveways, and to place drainage structures. The work zone speed limit is 60 mph. Expect lane closures and delays. The project is widening for a Super 2, and includes sub-grade work, surface treatment, base and surface hot-mix asphalt, widening structures, bridge rail, metal beam guard fence, signage, and permanent striping.

----------------------------------------

Cherokee County Jacksonville Maintenance plans to continue edge work on FM 23. Expect lane closures with flaggers managing traffic. Ditch maintenance is planned on roads around the county.

Cherokee County construction projects updates:

FM 22 Safety Widening and Bridge Replacement Project

Limits: From CR 1512 west of Gallatin, east to SH 110

Contractor: Stateline Construction, LLC

Cost: $5.5 million

Anticipated Completion Date: Summer 2022

The contractor is scheduled to continue bridge construction at Sandy Creek. The road is closed to traffic. Motorists should follow the marked detour route to navigate through the area. The project will widen the existing roadway, replace three bridges, and incorporate safety upgrades.

US 84 Widening

Limits: From 0.43 mi east of SH 110 in Rusk, northeast to the Rusk County line in Reklaw

Contractor: Madden Contracting Company, LLC

Cost: $7.9 million

Anticipated Completion Date: Summer 2022

The contractor is scheduled to continue right-of-way clearing. Expect lane closures with delays possible. The project will widen and resurface the roadway, and add safety upgrades.

FM 235 Safety Widening

Limits: From SH 110 going east to FM 2274

Contractor: Madden Contracting Company, LLC

Cost: $3.5 million

Anticipated Completion Date: Fall 2021

The contractor is scheduled to continue drainage upgrades. Expect lane closures with a pilot car managing traffic. The project will widen the existing roadway and incorporate safety upgrades.

FM 241 Safety Widening

Limits: From US 69 going southeast to SH 21

Contractor: A. L. Helmcamp, Inc.

Cost: $5.5 million

Anticipated Completion Date: Summer 2021

The contractor is scheduled to perform cleanup activities on this project that is widening the existing roadway and incorporating safety upgrades.

County Road Bridge Replacement Project

Limits: CR 2905 at Bowles Crk; CR 2614 at Beans Crk; CR 1504 at Turnpike Crk; CR 3203 at Mills Crk.

Contractor: Stateline Construction, LLC

Cost: $1.9 million

Anticipated Completion Date: Spring 2021

No work is scheduled on CR 3203 and CR 1504. Both roadways are open to traffic. Construction of the new bridges is ongoing on CR 2905 and CR 2614. Both roads are closed to through traffic. The projects are replacing the existing bridges at each location with new structures.

SH 204 Super-2 Widening Project

Limits: From US 79 in Jacksonville southeast to SH 110

Contractor: Madden Contracting Company, LLC

Cost: $13.7 million

Anticipated Completion Date: Summer 2021

The contractor is scheduled to perform seal coat and paving work as well as concrete driveway installation. Expect lane closures with a pilot car managing traffic. The project is adding passing lanes and includes safety upgrades.

US 69 Sidewalks in Jacksonville

Limits: From Nacogdoches St. to Tena St. in Jacksonville

Contractor: Highway 19 Construction, LLC

Cost: $507,099.00

Anticipated Completion Date: Spring 2021

No work is scheduled. The project is constructing sidewalks along US 69 in Jacksonville.

US 79 Rehabilitation Project

Limits: From 0.16 mile east of SH 110 to the Mud Creek Relief Bridge

Contractor: Madden Contracting Company, LLC

Cost: $8.2 million

Anticipated Completion Date: Spring 2021

The contractor plans to begin replacing the bridge joints. Expect lane closures and delays. The work zone speed limit is 60 mph. The project is rebuilding the roadway pavement and upgrading bridge rail.

----------------------------------------

Gregg County Longview Maintenance plans to conduct ditch cleaning operations on FM 1252 near the county line. Expect lane closures with flaggers providing traffic control. Weather permitting, bridge repairs will continue on various roadways around the county.

Gregg County construction projects updates:

I-20 Upgrades at Barber Road (New Project)

Limits: Exit and Entrance ramps to Barber Road

Contractor: Longview Bridge and Road

Cost: $1.49 million

Anticipated Completion Date: August 2021

The contractor will be working on drainage upgrades and driveways during night work. Motorists can expect lane closures on I-20 as well as alternating ramp closures, and delays, from 8 p.m. to 6 a.m. The project consists of widening of entrance and exit ramps, culverts, drainage upgrades, new metal beam guard fence and bridge rails on the Barber Road overpass, and an asphalt overlay.

US 80 Improvements Project

Limits: Eastman Road to 1 mile east

Contractor: Longview Road and Bridge

Cost: $1.09 million

Anticipated Completion Date: July 2021

Night work gets underway June 1 on this project that consists of constructing concrete curb and gutter in key locations in the median, an asphalt overlay, new signs, and striping. Construction will be conducted from 9 p.m. to 6 a.m., Sunday through Thursday nights. Expect lane closures and delays.

FM 2204, etc., Safety Improvement Project

Limits: US 259 Bypass to SH 322

Contractor: Stateline Construction

Cost: $3.88 million

Anticipated Completion Date: November 2021

The contractor will be working on drainage upgrades and driveways. Expect lane closures and delays. This project consists of culverts, safety end treatments, drainage upgrades, new metal beam guard fence and driveway asphalt.

Read the original post:
Project updates for the Week of June 7, 2021 - Texas Department of Transportation

China’s three-child policy is designed to bring on a baby boom, but its young adults are ‘lying flat’ – ABC News

China wants its young people to have more babies, but for some of the country's millennials, procreation couldn't be further from their minds.

This week's announcement of the three-child policy, aimed at encouraging couples in China's urban areas to have three children, has been met with ridicule.

Many social media users notedthey couldn't begin to afford a second child, let alone a third, in a country where a strict one-child policy has dramatically shaped the society.

On Weibo, user Sivan said: "I dare not have even one child, what's the point of talking about three?"

In fact, even before the family planning news broke, young people were opting in to anew social trend that is all about checking out from society and its pressures "tang ping", or "lying flat".

Lying flatrefers to a defeatist lifestyle, where peoplestop working, desiring material acquisition, and tap out ofany social life sometimes for good.

A declining birth rate and a rapidly ageing population loomas China's most pressing crises for the years to come.

The phrase has been coined by the young generationin response to increasing social anxiety and pressure, andaround the push to have more children, as well as the increasingly unaffordable associated costs.

Critics believe by lying flat, young people are participating in a kind of non-cooperationmovement,rather than surrendering themselves to China's oppressive work culture where they see little hope of social mobility.

For more than 35 years from 1980, couples in China's urban areas were prohibited from having more than one child, and faced large fines, or even forced abortion and sterilisation if caught.

The country eased that and moved to a two-child policy in 2015.

Now, China wants families to have three children, as it looksto boost its population after it was recently revealed the country's population growthhad dipped to its slowest pacesince the 1960s.

Immediately before the release of the three-child policy, several state media outlets in China published articles criticisinglying flatand called the trend shameful.

Shenzhen, widely regarded as China's Silicon Valley, is notorious for its 996 working culture, but a new policy that enforces paid leave and overtime payments for special industries could help reduce burnout.

Related social media groups havealso been censored.

On May 30, social media platform Doubanremoved a popular lying flatgroup, and many posts containingthe phrase were deleted.

Comments on China's social media platform Weibo following state media Xinhua's post on the three-child policy were quickly removed.

Another online votewas deleted after over 90 per cent of people ticked a box saying they would not consider a third child at all.

However, that has not shut down discussion another lying flatgroup on social media platform Baidu Tiebanow has over 180,000 members.

Reuters: Aly Song

Lucy Yu, 32, lives in Beijing and is expectingtwins in September.

In Lucy's eyes, lying flatis a fantasy.

Sheuses the phrase all the time but can never practiseit in reality.

"I use the word to mock myself, like others do too, but then just continue with what I've been doing," she said.

"It's a way young people come up with self-mockery. When we are too tired or feel a great deal of pressure, we want to 'lie flat'for a moment and leave the hard work behind.

"It's just a saying. How could you really lie flat?"

This is how Chinese women defied one-child policy to give birth in secret.

Ms Yu chatted with colleagues who are older than her they were born in the 1970safter the new policy was announced.

"They actually wanted a second child, but the two-child policy came too late," she said.

"That generation had siblings and they were relatively more affluent, but they didn't havethe chance."

But for younger people, it's a different story.

"Ordinary city, working-class people are struggling to make ends meet, so when the three-child policy comes out, they tend to feel that it's none of their business," she said.

"It's too tiresome and only creates unnecessary burdens for ourselves.

"I haven't counted how much money it will cost to have two children, but I'll raise them in a rich way if I have money, and raise them in a poor way if I don't have money. They'll grow up anyway."

Supplied

Anabel Ye is a 20-year-old university college student majoring in finance management, who identifies herself as one of the lying-down youth.

"I am a bit lying down already. There are too many amazing people everywhere," she said.

"Often, I found my efforts were not rewarded. Again and again, my passions were grounded."

Ms Ye believes the new policycould lead to a better future for China, but worries about the concerns it causes for the younger generation.

"I think the mortality rate of young people is also getting higher, many people died young because of physical and psychological issues associated with high pressure," she said.

She might have children in the future, but only one or two, and that willdepend on her circumstances.

"To give a child a good family and educational environment is not easy today, apart from that I also have to work. I don't think I'll have time and energy [to have more]," she said.

"Two children is ideal, but I also fear I might not want to get married or have children because of the increasing pressure."

Reuters:Guang Niu/GN/CP

Guo Fei, a professor of managementat Macquarie University's Centre for Workforce Futures, thinks the increased child limit is a good idea, but is uncertain if it will have the desired outcome.

"China's low fertility started, actually, [at]the same timewhen China started to experience rapid economic growth, and rapid urbanisation and modernisation," she said.

"The low fertility rate was not only the result of the one-child policy."

ProfessorGuo said the underlying reasons for China's low fertility wereactually socioeconomic.

Cost of living pressures are making things likeeducationbecomeunaffordable for many, and that has been deterring many from becoming parents.

Professor Guo thinks improving parental leave arrangements could help.

"If it's the company's burden, then couples or mothers who will have children will be discriminated against, they will be disadvantaged, because enterprise will be paying for their leave," she said.

"It's a norm and cultural attitude problem. In addition to the economic incentive, they also need to change attitudes towards childbearing women and older childbearingcouples."

If China doesn't do more to encourage people to have children, it could end up like South Korea, which has a negative fertility rate.

Butthose with the financialmeans will likely embrace the chance to have larger families, Professor Guo said.

"From the data we have from looking at the second child [policy], we have started to see women who have resources and higher education the well-off women tend to have higher intention to have a second child."

Reuters: Tingshu Wang

Wang Yaqiu, a China researcher fromHuman Rights Watch, has recently investigated China's previous two-child policy and gender discrimination in the workplace.

MsWang found the three-child policy might lead to companiesbecomingeven less willing to hire women.

Gender discrimination in the workplace worsened when the one-child policy was replacedwith the two-child policy.

"For 35 years, most professional women were only expected to take one period of maternity leave and had one child to take care of at home. That's what employers expect," Ms Wang said.

"When you hire a woman, if she already has a child, you know that she's not going to take another maternity leave.

"Companies started to worry. That makes companies even less willing to hire women."

China's government announcesit is scrapping a policy limiting couples to two children and will now allow them to have three.

Like Professor Guo, Ms Wang thinks a parental leave scheme andanti-discrimination laws need to be implemented along with the three-child policy.

"There is an issue with pregnancy-based firing at jobs," she said.

"It could be worse because now employers could potentially expect three maternity leaves."

Because there is no mandatory paternity leave,organisations don't face the same outlay forfathers who arehaving a child, so it's seen more costly to hire women than men in China.

To fix this, China needs to make equitable parental leaves for both men and women, Ms Wang said.

She believes the backlash against the three-child policy from the lying flat followers isfor two reasons.

"There are a lot of concerns with access to education, access to housing, access to health care, are those practical reasons that people don't want to have children."

The other reason, according to Ms Wang, is that the trauma left by the one-child policy still haunts many families today.

"To a lot of familiesit was the policy enforced in such a brutal way, through forced abortion, forced sterilisation. Now, the government found that the policy resulted in an aging population and we want more children," she said.

"Of course, people are going to become cynical'You controlled my body for so long, now you want me to go the other direction?'"

Go here to see the original:
China's three-child policy is designed to bring on a baby boom, but its young adults are 'lying flat' - ABC News

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO – GlobeNewswire

86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Nave Advanced Melanoma Patients in IOV-COM-202 Clinical Study

Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease

ASCO Update Conference Call and Webcast on Sunday, June 6 at 12 p.m. ET

SAN CARLOS, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced melanoma. The data are now available in an ePoster at the ASCO 2021 Annual Meeting.

Antonio Jimeno M.D., Ph.D., Professor of Medicine/Oncology and Otolaryngology at the University of Colorado School of Medicine stated, Anti-PD-1 therapy has become standard of care in frontline melanoma, yet we are still looking for ways to help more patients respond and to improve upon the depth and durability of responses. The 86% Overall Response Rate (ORR) for lifileucel in combination with pembrolizumab is remarkable and suggests a potential additive effect for early-line treatment of patients with melanoma. I look forward to investigating this treatment approach in additional patients with melanoma as well as in other tumor types such as head and neck squamous cancer.

Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, We are very pleased with the initial efficacy and safety results for lifileucel in combination with pembrolizumab in patients who are nave to anti-PD-1 therapy. We are particularly impressed by the complete response observations and noted conversion of several partial to complete responses over time. These data in melanoma also build upon our initial data for TIL in combination with pembrolizumab in head and neck cancer, supporting the broader potential for TIL in earlier anti-PD-1 nave treatment settings across indications.

Early data suggest the response rate of lifileucel plus pembrolizumab may be additive and confirm the potential feasibility and activity of this combination in patients with immune checkpoint inhibitor (ICI)-nave advanced melanoma. Cohort 1A in the IOV-COM-202 study is evaluating lifileucel in combination with pembrolizumab in patients who are nave to ICI, or anti-PD-1, therapy. Initial patients (n=7) enrolled in Cohort 1A had high tumor burden at baseline, and 71.4% had not received any prior systemic therapy.

Six of the seven patients had a confirmed objective response, representing an 86% ORR (2 complete responses (CR), 1 unconfirmed CR (uCR) who had not yet reached the confirmatory CR assessment, and 3 partial responses (PR)), with one best response of stable disease. Responses deepened over time and the CR/uCR rate was 43%. Poster data extraction was in April 2021 and the median follow up was 8.2 months. ORR was investigator-assessed per RECIST 1.1. In a subsequent data cut in May 2021, all ongoing responses continued.

The Cohort 1A results also demonstrated that lifileucel can be safely combined with pembrolizumab. The treatment-emergent adverse event (TEAE) profile was consistent with the underlying disease and known adverse event (AE) profiles of pembrolizumab, non-myeloablative lymphodepletion (NMA-LD) and IL-2. The median number of doses of IL-2 and pembrolizumab were six and 10, respectively.

Webcast and Conference CallIovance will host a webcast and conference call on Sunday, June 6, at 12:00 p.m. ET to discuss ASCO clinical data updates for lifileucel alone and in combination with pembrolizumab in patients with advanced melanoma. Iovance senior leadership, together with Dr. Omid Hamid of The Angeles Clinic, will present a summary of the ASCO data from Cohort 1A in the IOV-COM-202 study as well as the upcoming oral presentation of updated Cohort 2 data from the C-144-01 clinical study.

The conference call dial-in numbers are 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and the access code is 4858337. The live webcast can be accessed in the Investors section of the companys website at http://www.iovance.com. The archived webcast will be available for a year in the Investors section at http://www.iovance.com.

AboutIovance Biotherapeutics, Inc.Iovance aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer. TIL cells are extracted from a patients own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the companys TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit http://www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are forward-looking statements of Iovance Biotherapeutics, Inc. (hereinafter referred to as the Company, we, us, or our) within the meaning of the Private Securities Litigation Reform Act of 1995 (the PSLRA). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as predicts, believes, potential, continue, estimates, anticipates, expects, plans, intends, forecast, guidance, outlook, may, could, might, will, should or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of managements experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (FDA) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

CONTACTS

Iovance Biotherapeutics, Inc:Sara Pellegrino, IRCVice President, Investor Relations & Public Relations650-260-7120 ext. 264Sara.Pellegrino@iovance.com

Solebury Trout:Zara Lockshin646.378.2960zlockshin@soleburytrout.com

Read more:
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO - GlobeNewswire